NCT03033108View on ClinicalTrials.gov

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

November 30, 2017

Study Completion Date

December 31, 2017

Conditions
Stargardt DiseaseMacular Atrophy
Interventions
DRUG

Emixustat

Once daily, tablet for oral administration

Trial Locations (1)

75231

Dallas

Sponsors

Lead Sponsor

Kubota Vision Inc.
All Listed Sponsors
lead

Kubota Vision Inc.

INDUSTRY

NCT03033108 - Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease | Biotech Hunter | Biotech Hunter